rybelsus: Pharmaceutical manufacturers, suppliers, and packagers

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Novo	RYBELSUS	semaglutide	TABLET;ORAL	213051	NDA	Novo Nordisk	0169-4303-30	30 TABLET in 1 BOTTLE, GLASS (0169-4303-30)	2019-09-20
Novo	RYBELSUS	semaglutide	TABLET;ORAL	213051	NDA	Novo Nordisk	0169-4303-99	30 TABLET in 1 BOTTLE, GLASS (0169-4303-99)	2019-09-20
Novo	RYBELSUS	semaglutide	TABLET;ORAL	213051	NDA	Novo Nordisk	0169-4307-30	30 TABLET in 1 BOTTLE, GLASS (0169-4307-30)	2019-09-20
Novo	RYBELSUS	semaglutide	TABLET;ORAL	213051	NDA	Novo Nordisk	0169-4314-30	30 TABLET in 1 BOTTLE, GLASS (0169-4314-30)	2019-09-20
Novo	RYBELSUS	semaglutide	TABLET;ORAL	213051	NDA	Novo Nordisk	0169-4804-30	30 TABLET in 1 BOTTLE, PLASTIC (0169-4804-30)	2019-09-20
Novo	RYBELSUS	semaglutide	TABLET;ORAL	213051	NDA	Novo Nordisk	0169-4809-30	30 TABLET in 1 BOTTLE, PLASTIC (0169-4809-30)	2019-09-20
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: July 30, 2025

Introduction

Rybelsus (semaglutide) is an oral prescription medication developed for the management of type 2 diabetes mellitus. As the first oral GLP-1 receptor agonist approved by the FDA, Rybelsus has garnered significant attention from healthcare providers, patients, and pharmaceutical supply chains. Ensuring a reliable supply of Rybelsus involves an intricate network of suppliers spanning raw material providers, manufacturing facilities, and distribution channels. This analysis offers a comprehensive overview of the key suppliers involved in Rybelsus's supply chain, evaluating their roles, market significance, and the implications for stakeholders.

Active Pharmaceutical Ingredient (API) Suppliers

The foundation of any pharmaceutical product’s supply chain lies in the procurement of high-quality Active Pharmaceutical Ingredients (APIs). For Rybelsus, semaglutide—a synthetic peptide—serves as its API. Production of peptides like semaglutide is complex, requiring specialized synthesis processes, stringent quality controls, and advanced manufacturing technologies.

1. Chinese and Indian API Manufacturers

China and India dominate the global API manufacturing landscape, accounting for approximately 60-70% of the world's API production capacity. Key players involved in peptide API manufacturing for semaglutide include:

Jiuzhou Pharmaceutical (China): Known for peptide synthesis capabilities, Jiuzhou supplies APIs for various therapeutic areas, including diabetes medications. Although specific supply contracts for semaglutide are confidential, Chinese API manufacturers are prominent in this space due to cost efficiency and technological capacity.
Sichuan Peptide Biotech (China): This company specializes in peptide synthesis and custom API manufacturing, potentially serving as a supplier for semaglutide APIs, aligning with global manufacturing demands.
Boehringer Ingelheim (Germany): While primarily involved in research, this multinational has extensive peptide synthesis expertise. It supplies high-quality APIs and collaborates with manufacturing partners.
Caslo Biosciences (India): An emerging player in peptide synthesis, Caslo offers APIs for clinical development and commercial scale, suggesting potential involvement in semaglutide production.

2. Contract Manufacturing Organizations (CMOs)

Major pharmaceutical companies, including Novo Nordisk—developer of Rybelsus—may utilize CMOs to produce APIs at scale. These CMOs often have regulated facilities capable of peptide synthesis, such as:

Samsung Biologics (South Korea): Known for biopharmaceutical manufacturing, Samsung's capacity spans complex peptide APIs, providing backup or supplementary API synthesis.
Lonza (Switzerland): A global contract development and manufacturing organization with peptide API manufacturing capabilities, offering scalable, high-quality supplies for confidentiality-sensitive compounds like semaglutide.

Formulation and Finished Drug Product Suppliers

Beyond API sourcing, the formulation process transforms semaglutide into the final orally administered Rybelsus tablet. This step involves excipient sourcing, tablet manufacturing, and quality assurance.

1. Pharmaceutical Formulation Manufacturers

Novo Nordisk: As the originator of Rybelsus, Novo Nordisk oversees the formulation, production, and distribution of the drug. The Danish company operates multiple manufacturing plants globally, including facilities dedicated to oral formulations and peptides for injectable and oral use.
Third-party Contract Manufacturers: While Novo Nordisk primarily handles production internally, it collaborates with CMOs such as Catalent and Recipharm for contract manufacturing of finished drug products to ensure supply flexibility.

2. Excipients and Additives Suppliers

Manufacturing oral tablets necessitates excipients like binders, fillers, disintegrants, and coating agents:

Evonik Industries (Germany): Supplies high-quality excipients used in Rybelsus formulations.
JRS Pharma (Germany): A supplier of disintegrants and binders for oral solid dosage forms.
KP Specialty Products (USA): Provides various excipients and polymers suitable for peptide-based tablets.

Distribution and Supply Chain Logistics

Efficient distribution ensures steady availability to pharmacies, healthcare facilities, and patients worldwide.

1. Wholesale Distributors

Major pharmaceutical distributors such as McKesson, AmerisourceBergen, and Cardinal Health facilitate Rybelsus's global distribution, aligning with regulatory and quality standards.

2. Logistics Providers

Specialized cold chain and temperature-controlled logistics firms, including DHL Supply Chain and Kuehne + Nagel, secure the integrity of sensitive products during transit and storage.

Regulatory and Quality Considerations

Suppliers must adhere to strict Good Manufacturing Practices (GMP) set by authorities like the FDA, EMA, and PMDA. Certification, audits, and compliance underpin the credibility of suppliers and guarantee product quality.

Supply Chain Risks:

Geopolitical factors and trade restrictions can disrupt APIs' supply, especially those reliant on Chinese and Indian manufacturers.
Capacity constraints amid global demand surges necessitate diversified sourcing strategies.
Intellectual property considerations, particularly in peptide synthesis, influence supplier relationships and licensing agreements.

Implications for Stakeholders

Pharmaceutical Companies (e.g., Novo Nordisk): Must cultivate a robust and diversified supplier base to mitigate risks related to supply interruptions.
Healthcare Providers: Depend on transparent, consistent supply for treatment continuity.
Patients: Rely on secure access facilitated by reliable suppliers and efficient logistics.
Investors: Should monitor supplier stability and capacity expansion to gauge Rybelsus’s market viability.

Key Takeaways

Multi-tiered supply chain: Rybelsus's supply hinges on complex API manufacturing, formulation, packaging, and distribution channels involving multiple regional suppliers.
Predominance of Chinese and Indian API producers: These regions supply most peptide APIs globally, highlighting geopolitical and quality assurance considerations.
Strategic partnerships: Novo Nordisk leverages internal manufacturing and partnerships with CMOs for flexibility and resilience.
Regulatory compliance: High standards are imperative across all suppliers to ensure safety, efficacy, and regulatory approval status.
Supply chain resilience: Diversifying sources and investing in supply capacity expansion are critical to meet global demand.

FAQs

Who are the main API suppliers for semaglutide used in Rybelsus?
Most semaglutide APIs are produced by Chinese and Indian peptide manufacturers, with key players like Jiuzhou Pharmaceutical and Sichuan Peptide Biotech, supplemented by CMOs such as Samsung Biologics and Lonza.
Does Novo Nordisk manufacture Rybelsus’s APIs and formulations in-house?
Yes, Novo Nordisk handles core manufacturing processes at its facilities in Denmark and collaborates with CMOs for additional production and formulation needs.
Are there geopolitical risks associated with Rybelsus’s supply chain?
Yes. Heavy reliance on Chinese and Indian API suppliers introduces risks related to trade tensions, export restrictions, and supply disruptions, emphasizing the need for diversified sourcing.
What role do excipient suppliers play in Rybelsus manufacturing?
Excipients from companies like Evonik Industries and JRS Pharma enable the formulation of stable, bioavailable tablets, directly impacting product quality and efficacy.
How is logistics management critical for Rybelsus?
Effective cold chain logistics and temperature-controlled distribution networks managed by providers like DHL ensure the integrity of Rybelsus during transit, preventing quality degradation.

References

[1] FDA Approves Rybelsus (semaglutide) for Type 2 Diabetes, U.S. Food and Drug Administration, 2019.
[2] Novo Nordisk. Rybelsus (semaglutide) Product Information, 2023.
[3] Peptide API Market Overview, Grand View Research, 2022.
[4] Contract Manufacturing Organizations in Biopharma, Pharma Intelligence Report, 2022.
[5] Supply Chain Risks in Peptide Drugs, European Pharmacopoeia, 2021.

Suppliers and packagers for rybelsus

rybelsus

Suppliers for the Pharmaceutical Drug: Rybelsus